F16.221
Hallucinogen dependence with intoxication with delirium
Clinical Classification Guidelines
Medical Intelligence & Overview
ICD-10 code F16.221 refers to a specific mental health condition characterized by dependence on hallucinogenic drugs combined with periods of intoxication accompanied by delirium. This condition highlights the complex effects of certain mind-altering substances, where ongoing use can lead to physical and psychological dependence, and exposure can occasionally result in episodes of severe mental confusion or delirium. Recognizing the signs and understanding the nature of this disorder are essential steps toward appropriate treatment and management.
Causes & Symptoms
Clinical Causes: Repeated use of hallucinogenic substances such as LSD, psilocybin, mescaline, or similar drugs. Genetic predisposition or family history of substance dependence or mental health disorders. Environmental factors including peer influence, stress, or exposure to environments where drug use is prevalent. Psychological factors such as underlying mental health issues, including anxiety or depression, which may increase susceptibility to substance dependence. Lack of awareness or education about the risks associated with hallucinogen use.
Key Symptoms: Persistent craving or compulsive need to use hallucinogens. Loss of control over drug intake despite negative consequences. Tolerance, requiring increasingly higher doses to achieve the desired effects. Detrimental physical, psychological, or social consequences from drug use. Episodes of intoxication leading to confusion, disorientation, or modifying perceptions. Delirium characterized by severe mental confusion, hallucinations, agitation, and fluctuating levels of consciousness. Withdrawal symptoms such as sweating, nausea, tremors, or agitation upon cessation. Changes in mood, perception, or thought processes that often impair daily functioning.
Diagnostic & Treatment
Diagnosis Path: Diagnosis involves clinical assessment through patient interviews, mental status examinations, and a detailed history of drug use. Healthcare providers look for signs of substance dependence alongside episodes of delirium during intoxication. Laboratory tests may include toxicology screenings to detect hallucinogenic substances, but diagnosis is primarily based on clinical presentation aligned with ICD-10 criteria for substance dependence and delirium episodes.
Treatment Protocols: Managing hallucinogen dependence with intoxication and delirium requires a comprehensive approach that may include: - Detoxification: supervised withdrawal to manage physical dependence. - Psychotherapy: counseling, cognitive-behavioral therapy, and support groups to address dependence patterns. - Medication: while there are no specific medications approved for hallucinogen dependence, medications may be used to treat co-occurring mental health issues or manage symptoms during withdrawal. - Educational initiatives to inform about the risks involved and strategies to prevent relapse. - Supportive care during episodes of delirium, ensuring safety and addressing agitation or hallucinations. Each treatment plan should be tailored to the individual's specific needs, with close monitoring by healthcare professionals.
Clinical Advice & FAQs
Billing Guidance
Is F16.221 a billable ICD-10 code?
Yes, F16.221 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report F16.221?
Clinical documentation must specify the nature of Hallucinogen dependence with intoxication with delirium and any associated comorbidities for accurate reporting.
Cite this Clinical Reference